An IgG1 murine monoclonal anti-idiotype antibody (Ab2), ACA-125, was developed to bind to anti-CA 125 antibodies. ACA-125 mimics the tumor-associated antigen CA-125, which can be detected in about 80% of... This new concept of oncological immunotherapy consists of an attempt to trigger the immune system of the host to respond against tumor cells.
- Mechanism
- Curator reviewed
To create ACA-125, a hybridoma cell was adapted to serum-free medium and antibody was produced in a hollow fiber cell culture system. ACA 125 (Ab2) showed high affinity for the paratope of Abl. Binding of Ab2 to Abl is completely inhibited by the nominal antigen. Application of fragments of ACA 125 to rats lead to an anti-CA 125 immunity by production of IgG and IgM antiantiidiotypic antibodies (Ab3) that bind to both ACA 125 and CA 125.
- Primary indication
- Investigated for use/treatment in ovarian cancer.Curator reviewed
- Code names
- ACA 125
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with ACA 125, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account